Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using the company's PRINT? technology to transform the lives of patients. The company is focused on the development of its product candidates for which it holds commercial rights: LIQ861, which is being evaluated for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure.
  • TickerLQDA
  • ISINUS53635D2027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology

Analysts

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

No Additional CMC Requirements for LIQ861/PAH NDA; Filing by Early Q1:20

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

No Additional CMC Requirements for LIQ861/PAH NDA; Filing by Early Q1:20

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch